Inflammation and the degenerative diseases of aging

Annals of the New York Academy of Sciences

Volumn 1035, Issue , 2004, Pages 104-116

  McGeer, Patrick L ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Atherosclerosis; Myocardial infarction; NSAIDs; Osteoarthritis; Parkinson's disease; Rheumatoid arthritis; Tauopathies

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANAPHYLATOXIN; ANTIINFLAMMATORY AGENT; CD23 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT; CYTOKINE; FREE RADICAL; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTRAXIN; PROSTAGLANDIN; PROTEINASE; PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CONFERENCE PAPER; DEGENERATIVE DISEASE; EXTRACELLULAR MATRIX; HEALING; HEART INFARCTION; HIPPOCAMPUS; HUMAN; MICROGLIA; OSTEOARTHRITIS; OXIDATIVE STRESS; PARKINSON DISEASE; PHAGOCYTE; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SUBSTANTIA NIGRA; TAUOPATHY; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 14944352071     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1332.007     Document Type: Conference Paper

References (86)

1. NEUROINFLAMMATION WORKING GROUP. 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging 21: 383-421.
2. MCGEER, E.G. & P.L. MCGEER. 2003. Inflammatory processes in Alzheimer's disease. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 27: 741-749.
3. MCGEER, P.L. & E.G. MCGEER. 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10: S3-S7.
4. MADHAVI, T. et al. 2003. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin. Neuropharmacol. 26: 18-23.
5. MCGEER, P.L. & E.G. MCGEER. 2002. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26: 459-470.
6. HAYMAKER, W. & R.D. ADAMS, Eds. 1982. Histology and Histopathology of the Nervous System, pp. 1150-1173. Charles C. Thomas. Springfield, IL.
7. METCHNIKOFF, E. 1892. Lecons sur la pathologie comparée de l'inflammation. Masson. Paris.
8. DEL RIO HORTEGA, P. 1919. El 'tercer elemento' de los centros nerviosos. Poder fagocitario y movilidad de la microglia. Bol. Soc. Esp. Biol. Ano. 9: 154-166.
9. VAN FURTH, R. 1982. Current view on the mononuclear phagocyte system. Immunobiology 161: 178-185.
10. DAVIS, R.L. & D.M. ROBERTSON, Eds. 1991. Textbook of Neuropathology. Second edition, pp. 141-163. Williams & Wilkins. Baltimore.
11. MCGEER, P.L. & E.G. MCGEER. 1995. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative disease. Brain Res. Rev. 21: 195-218.
12. LUBER-NAROD, J. & J. ROGERS. 1988. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci. Lett. 94: 265-273.
13. MCGEER, P.L. et al. 1988. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76: 550-557.
14. PENFIELD, W. 1925. Microglia and the process of phagocytosis in gliomas. Am. J. Pathol. 1: 77-89.
15. LANGSTON, J.W. et al. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine exposure. Ann. Neurol. 46: 598-605.
16. MCGEER, P.L. et al. 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine administration. Ann. Neurol. 54: 599-604.
17. YASOJIMA, K. et al. 2001. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 21: 1214-1219.
18. YASOJIMA, K. et al. 1998. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ. Res. 83: 860-869.
19. MOSSER, D.M. 2003. The many faces of macrophage activation. J. Leukoc. Biol. 73: 209-212.
20. SCHWAB, C. et al. 2004. Transgenic mice overexpressing amyloid beta-protein are an incomplete model of Alzheimer disease. Exp. Neurol. 188: 52-64.
21. COLTON, C.A. & D.I. GILBERT. 1987. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223: 284-288.
22. KLEGERIS, A. & P.L. MCGEER. 1994. Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. J. Neuroimmunol. 53: 83-90.
23. BUTTERFIELD, D.A. & J. KANSKI. 2001. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Aging Dev. 122: 945-962.
24. WILLIAMSON, K.S. et al. 2002. The nitration product 5-nitro-gamma- tocopherol is increased in the Alzheimer brain. Nitric Oxide 6: 221-227.
25. BANATI, R.B. et al. 1993. Cytotoxicity of microglia. Glia 7: 111-118.
26. GIULIAN, D. et al. 1996. Specific domains of β-amyloid from Alzheimer plaque elicit neuronal killing in human microglia. J. Neurosci. 16: 6021-6037.
27. KLEGERIS, A. & P.L. MCGEER. 2000. Interaction of various intrasignalling mechanisms involved in mononuclear phagocyte toxicity towards neuronal cells. J. Leukoc. Biol. 67: 127-133.
28. KLEGERIS, A. et al. 1997. Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J. Neuroimmunol. 78: 152-161.
29. MCGEER, P.L. & E.G. MCGEER. 2001. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22: 799-809.
30. WEBSTER, S. et al. 1997. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18: 415-421.
31. ROGERS, J. et al. 1992. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89: 10016-10020.
32. MCGEER, E.G. et al. 2001. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory disorders. Neurobiol. Aging 22: 843-848.
33. YASOJIMA, K. et al. 2001. High stability of mRNAs postmortem and protocols for their assessment by RT-PCR. Brain Res. Protocols 8: 212-218.
34. FURLONG, S.T. et al. 2000. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Immunopharmacology 48: 199-212.
35. FIANE, A.E. et al. 1999. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 6: 52-65.
36. SCHWARTZ, C.F. et al. 1999. Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate. J. Surg. Res. 86: 24-28.
37. TANHEHCO, E.J. et al. 1999. Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J. Cardiovas. Pharm. 34: 153-161.
38. JIANG, H. et al. 1992. Localization of sites through which C-reactive protein binds to and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J. Exp. Med. 175: 1373-1379.
39. HICKS, P.S. et al. 1992. Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149: 3689-3694.
40. KALARIA, R.N. & I. GRAHOVAC. 1990. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res. 516: 349-353.
41. YASOJIMA, K. et al. 2000. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887: 80-89.
42. AKIYAMA, H. et al. 1991. Association of amyloid P component with complement proteins in neurologically diseased tissue. Brain Res. 548: 349-352.
43. BLACKER, D. et al. 1998. Alpha-2-macroglobulin is genetically associated with Alzheimer disease. Nature Genetics 19: 357-360.
44. COLLINS, J.S. et al. 2000. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer disease genetics initiative. Am. J. Med. Genet. 96: 823-830.
45. Du, Y. et al. 2000. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 55: 480-483.
46. GRIMALDI, L.M. et al. 2000. Association of early-onset Alzheimer's disease with an interleukin-1a gene polymorphism. Ann. Neurol. 47: 361-365.
47. KAMBOH, M.I. et al. 1997. Genetic effect of alpha-1-antichymotrypsin on the risk of Alzheimer disease. Genomics 40: 382-384.
48. LICASTRO, F. et al. 2000. Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affect IL-6 plasma levels. Neurobiol. Aging 21: S38.
49. LICASTRO, F. et al. 2000. Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann. Neurol. 48: 388-391.
50. MCCUSKER, S.M. 2001. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357: 436-439.
51. NICOLL, J.A.R. et al. 2000. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47: 365-368.
52. PAPASSOTIROPOULOS, A. et al. 1999. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45: 666-668.
53. REBECK, G.W. 2000. Confirmation of the genetic association of interleukin-1α with early onset sporadic Alzheimer's disease. Neurosci. Lett. 293: 75-77.
54. HEDLEY, R. et al. 2002. Association of interleukin-1 polymorphisms with Alzheimer's disease in Australia. Ann. Neurol. 51: 795-797.
55. SCHULTE, T. et al. 2000. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci. Lett. 326: 70-72.
56. MCGEER, P.L. et al. 2000. Association of interleukin-1β polymorphism with idiopathic Parkinson's disease. Neurosci. Lett. 326: 67-69.
57. STRITTMATTER, W.J. et al. 1993. Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 1977-1981.
58. MCGEER, P.L. & E.G. MCGEER. 2001. Polymorphisms in inflammatory genes enhance the risk of Alzheimer disease. Arch. Neurol. 58: 1790-1792.
59. ALLDRED, A. 2001. Etanercept in rheumatoid arthritis. Exp. Opin. Pharmacother. 1: 1137-1148.
60. HAMILTON, K. & E.W. CLAIR. 2000. Tumour necrosis factor-alpha blockade: a new era for the effective management of rheumatoid arthritis. Exp. Opin. Pharmacother. 1: 1041-1052.
61. FEAGAN, E.G. et al. 2001. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can. J. Clin. Pharmacol. 8: 188-198.
62. CHAPMAN, G.A. et al. 2000. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. 20: 2-6.
63. ZUJOVIC, V. et al. 2000. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29: 305-315.
64. BROE, G.A. et al. 2000. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol. 57: 1586-1591.
65. MCGEER, P.L. et al. 1996. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 147: 425-432.
66. SZEKELY, C.A. et al 2004. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23: 159-169.
67. STEWART, W.F. et al. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632.
68. VELD, B.A. et al. 2001. Non-steroidal antiinflammatory drug use and risk of Alzheimer's disease. New Engl. J. Med. 345: 1515-1521.
69. WOLFSON, C. et al. 2002. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? Neuroepidemiology 21: 81-86.
70. CHEN, H. et al. 2002. Nonsteroidal antiinflammatory drugs and the risk of Parkinson's disease. Movement Dis. 17: S143-S144.
71. AISEN, P.S. et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54: 588-593.
72. AISEN, P.S., et al. 2002. Randomized pilot study of nimesulide in Alzheimer's disease. Neurology 58: 1050-1054.
73. SAINALI, S.M. et al. 2000. Results of a double-blind, placebo-controlled study of celecoxib for the progression of Alzheimer's disease. In Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy, p. 180.
74. VAN GOOL, W.A. et al. 2001. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet 358: 455-460.
75. HOSCHL, C. & T. HAJEK. 2001. Hippocampal damage mediated by corticosteroids-a neuropsychiatric research challenge. Eur. Arch. Psychiatry & Clin. Neurosci. 251: II81-II88.
76. YASOJIMA, K. et al 1999. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830: 226-236.
77. MCGEER, P.L. 2000. Cyclo-oxygenase-2 inhibitors.Drugs Aging 17: 1-11.
78. STEIN, M. et al 2000. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27: 2927-2931.
79. ROGERS, J. et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611.
80. SCHARF, S. et al. 1999. A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease. Neurology 53: 197-201.
81. ARAI, H. et al. 2000. A new interventional strategy for Alzheimer's disease by Japanese herbal medicine. Jap. J. Ger. 37: 212-215.
82. KLEGERIS, A. et al. 1999. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology 38: 1017-1025.
83. AISEN, P.S. et al. 2003. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. J. Am. Med. Assoc. 289: 2819-2826.
84. CAPELL, H.A. 2001. Disease modifying antirheumatic drugs: longterm safety issues. J. Rheumatol. (Suppl.) 62: 10-15.
85. WALLACE, J.L. et al. 1995. Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. Agents Actions (Suppl.) 46: 121-129.
86. YASOJIMA, K. et al. 1999. Complement regulators Cl inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res. 833: 297-301.